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Summary
 
Cytokines stimulate granulopoiesis through signaling via receptors whose expression is con-
trolled by lineage-specific transcription factors. Previously, we demonstrated that granulocyte
colony-stimulating factor (G-CSF) receptor mRNA was undetectable and granulocyte matura-
tion blocked in CCAAT enhancer binding protein 
 
a
 
 (C/EBP
 
a
 
)-deficient mice. This pheno-
type is distinct from that of G-CSF receptor
 
2
 
/
 
2
 
 mice, suggesting that other genes are likely to
be adversely affected by loss of C/EBP
 
a
 
. Here we demonstrate loss of interleukin 6 (IL-6) re-
ceptor and IL-6–responsive colony-forming units (CFU-IL6) in C/EBP
 
a
 
2
 
/
 
2
 
 mice. The ob-
served failure of granulopoiesis could be rescued by the addition of soluble IL-6 receptor and
IL-6 or by retroviral transduction of G-CSF receptors, demonstrating that loss of both of these
receptors contributes to the absolute block in granulocyte maturation observed in C/EBP
 
a
 
-def-
icient hematopoietic cells. The results of these and other studies suggest that additional C/EBP
 
a
 
target genes, possibly other cytokine receptors, are also important for the block in granulocyte
differentiation observed in vivo in C/EBP
 
a
 
-deficient mice.
Key words: CCAAT enhancer binding protein • knockout mice • colony-forming unit • 
hematopoiesis • myelopoiesis
 
M
 
ultipotential hematopoietic stem cells differentiate
into all of the different lineages of blood cells. The
processes of distinct lineage differentiation is regulated by
distinct transcription factors such as GATA-1 for erythroid
cells, PU.1 for myeloid and B cells, and CCAAT enhancer
binding protein 
 
a
 
 (C/EBP
 
a
 
)
 
1
 
 for granulocytes (1, 2). The
molecular basis for how these factors regulate hematopoie-
tic stem cell differentiation is still not clear. Interestingly,
all of these factors can positively regulate the expression
of lineage-specific growth factor receptors. For example,
GATA-1 activates the erythropoietin receptor promoter
(3), PU.1 is critical for M-CSF receptor promoter activity
(4), and C/EBP
 
a 
 
is an important regulator of G-CSF re-
ceptor promoter function (5). Therefore, one possible
mechanism of transcription factor regulation of lineage dif-
ferentiation is through activation of cell type–specific cy-
tokine receptors.
C/EBP
 
a 
 
is a member of the C/EBP transcription factor
family (6). Other members of this family include C/EBP
 
b
 
,
or NF-IL6, which is critical for macrophage activation (7,
8), and C/EBP
 
e
 
, which regulates granulocyte maturation at
a very terminal stage (9). C/EBP
 
a 
 
has been shown to regu-
late a number of hepatocyte and adipocyte genes (10, 11).
Targeted deletion of the C/EBP
 
a 
 
gene in mice disrupts
normal glucose metabolism, and homozygous newborn an-
imals die from hypoglycemia within 8 h of birth (12, 13).
In the hematopoietic system, C/EBP
 
a 
 
is expressed specifi-
cally in both human and murine myeloid cells (14). It up-
regulates several myeloid gene promoters, such as G-CSF
receptor (5), myeloperoxidase (15, 15a), and neutrophil
 
1
 
Abbreviations used in this paper:
 
 C/EBP, CCAAT enhancer binding pro-
tein; CFU-GM, GM-CSF–responsive CFU; CFU-IL3 and -IL6, IL-3
and IL-6–responsive CFU, respectively; RT, reverse transcription; SCF,
stem cell factor.
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elastase (15a, 16). Recent studies have demonstrated that
C/EBP
 
a 
 
expression is selectively maintained during granu-
locytic differentiation, but is markedly downregulated with
monocytic differentiation (17).
Previously, we reported that granulocyte maturation was
completely blocked in C/EBP
 
a
 
-deficient mice, but T cell,
B cell, and macrophage subsets were normal. Expression of
G-CSF receptor mRNA was profoundly and selectively re-
duced, whereas levels of M-CSF receptor, GM-CSF recep-
tor 
 
a
 
, and IL-3 receptor 
 
a 
 
mRNA were all comparable to
wild-type (18). No defects were observed in C/EBP
 
a
 
1
 
/
 
2
 
mice. However, mice with a targeted disruption of the
G-CSF receptor only have a quantitative defect in granu-
lopoiesis; mature granulocyte are still detected at a level
12% of wild-type (19). These results suggest that in addi-
tion to G-CSF receptor, other genes were likely to be af-
fected by loss of the C/EBP
 
a 
 
gene.
Multiple cytokines are involved in the regulation of
granulopoiesis, including G-CSF, GM-CSF, IL-3, and IL-6
(20, 21). Mice that have been treated with IL-6 have an in-
creased number of peripheral neutrophils (22). Double
transgenic mice which coexpress human IL-6 and soluble
IL-6 receptor demonstrate dramatic increases of white blood
cells consisting mainly of neutrophilic granulocytes com-
pared with wild-type, single transgenic mice (23). Coadmin-
istration of recombinant human IL-6 and G-CSF to irradia-
tion-induced myelosuppressed mice caused a synergistic
increase in the GM-CSF–responsive CFU (CFU-GM) in
peripheral blood and bone marrow (24). Loss of IL-6 in
G-CSF receptor–deficient mice leads to a significant fur-
ther reduction in the number of mature neutrophils in pe-
ripheral blood and bone marrow (25). All of these data in-
dicate that IL-6 also regulates granulopoiesis, and that IL-6
and G-CSF may have a synergistic effect on myelopoiesis.
The biological effects of IL-6 are known to be mediated
through their unique cell surface receptors (21). IL-6 re-
ceptors are expressed in many cell types, including plasma-
cytoma cells, macrophages, T cells, B cells, and pre-B cells
(26). During embryogenesis, it is expressed constitutively at
readily detectable levels that do not change significantly
during in vitro embryoid body development and blastocyst
development (27). In the hematopoietic system, the ex-
pression of IL-6 receptor rapidly decreases to undetectable
levels during erythroid differentiation, and slowly decreases
during granulocyte differentiation (28). IL-6 has been
shown to bind to the IL-6 receptor with low affinity (29).
However, the presence of gp130, a signal transducer not
only for IL-6 but also for leukocyte inhibition factor (LIF),
Oncostatin M, IL-11, and ciliary neurotrophic factor, to-
gether with IL-6 will result in high-affinity IL-6 binding
and subsequent signal transduction (30). The cytoplasmic
domain of the IL-6 receptor is apparently not required for
high-affinity IL-6 binding and signal transduction, since the
soluble form of the IL-6 receptor, when complexed to IL-6,
can also trigger high-affinity IL-6 binding and signaling on
target cells lacking IL-6 receptor but expressing gp130 (31).
Interestingly, G-CSF receptor and gp130 share significant
similarity within their cytoplasmic domains (21, 30).
Here, we demonstrate that the IL-6 receptor is markedly
downregulated in C/EBP
 
a
 
2
 
/
 
2
 
 mice, whereas the expres-
sion level of gp130 in C/EBP
 
a
 
2
 
/
 
2
 
 mice is comparable
with the level in wild-type mice. C/EBP
 
a
 
2
 
/
 
2
 
 progenitors
do not respond to IL-6 alone in vitro, but a small number
of precursors can differentiate to metamyelocytic granulo-
cytes by the addition of soluble IL-6 receptor to the cul-
ture. Addition of G-CSF together with soluble IL-6 recep-
tor and IL-6 induces formation of mature segmented
granulocytes. C/EBP
 
a
 
2
 
/
 
2
 
 fetal liver hematopoietic cells
also can be rescued in vitro by transduction of G-CSF re-
ceptors into the cells by using retroviral infection. These
studies demonstrate that the IL-6 receptor is a second ma-
jor target gene for C/EBP
 
a
 
. Restoration of expression of
either receptor can restore granulopoiesis in vitro, demon-
strating that they are important functional targets for C/
EBP
 
a
 
.
 
Materials and Methods
 
Hematological Analysis.
 
Human recombinant IL-6 (500 ng/
ml), soluble IL-6 receptor (100 ng/ml), and G-CSF (1,000 U/
ml), which are all active on murine cells, and murine recombi-
nant IL-3 (300 U/ml) and GM-CSF (10 ng/ml) were used in the
CFU assays. Methylcellulose culture of single cell suspensions of
fetal liver cells was performed in IMDM medium containing
0.8% methylcellulose and either 30% heat-inactivated fetal bovine
serum for IL-6 and G-CSF CFU assays, or 20% heat-inactivated
serum for the GM-CSF and IL-3 CFU assays. 10% Chinese ham-
ster ovary cell–conditioned medium from cells stably transfected
with a stem cell factor (SCF) expression vector was used as a
source of SCF, and 10% WEHI-3–conditioned medium was used
as a source of IL-3 for liquid cultures. Colonies were counted at
days 7–9. Two to four colonies were pooled and cytocentrifuged
onto glass slides daily after day 7. The slides were stained with
Wright-Giemsa (Diff-Quik; Baxter Healthcare Corp., Deerfield,
IL) according to the manufacturer’s protocol.
 
Northern Blot Analysis.
 
Total RNA was isolated from mouse
fetal liver, adult bone marrow, spleen, thymus, and peritoneal
cells 48 h after thioglycollate stimulation, at which time 90% of the
cells are macrophages. Total RNA was purified by guanidine iso-
thiocyanate extraction and cesium chloride gradient. Poly A
 
1
 
 RNA
was purified by oligo-(dT) chromatography. Northern blot analy-
sis was performed as described previously (32). The probe used
was a 1.6-kb SacI fragment of murine IL-6 receptor cDNA (26).
 
Quantitative PCR.
 
Quantitative PCR analysis to determine
receptor mRNA levels was performed as described previously
(33). In brief, total RNA was purified from day 19 C/EBP
 
a
 
wild-type or 
 
2
 
/
 
2
 
 fetal liver. In vitro transcription of plasmid
pSPCR1 mRNA was used as a standard. The standard mRNA
concentration was measured by UV absorption after purification
by oligo-(dT) chromatography. The length of the IL-6 receptor
RNA molecules obtained from transcription of pSPCR1 as the
template was 520 bp, and 1 
 
m
 
g of RNA equals 1.76 
 
3 
 
10
 
12
 
 mol-
ecules. First-strand cDNA from fetal liver RNA was synthesized
by reverse transcription (RT) according to the manufacturer’s
protocol (Boehringer Mannheim Corp., Indianapolis, IN). The
reaction contained 2 
 
m
 
g of total cellular RNA and decreasing
amounts of standard RNA starting at 10
 
8
 
 molecules. 1 
 
m
 
l of RT
product was used for PCR. The annealing temperature for
G-CSF receptor was 52
 
8
 
C; for the IL-6 receptor, 52
 
8
 
C; and for 
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gp130, 54
 
8
 
C. The oligonucleotides used were as follows: for
the IL-6 receptor, 5
 
9
 
-primer, ACCACGAGGATCAGTACGAA,
and 3
 
9
 
-primer, TGTTGTCATAAGGGCTCTGT; for gp130,
5
 
9
 
-primer, TTGAAGTCTGGGTGGAAGCA, and 3
 
9
 
-primer,
GGTGGTCTGGATGGTCTGTC; for the G-CSF receptor,
5
 
9
 
-primer, TCCGTCACCCTAAACATCTC, and 3
 
9
 
-primer,
TGGAAGGTTTCCTCTGTCAT. PCR amplification was con-
tinued for 30 cycles. 5 
 
m
 
l of each PCR product was electro-
phoresed in 5% polyacrylamide gels in 1
 
3 
 
TBE buffer. Quantita-
tion of autoradiography of dried gels was performed using a
PhosphorImager and ImageQuant densitometry software (Molec-
ular Dynamics, Sunnyvale, CA).
 
Flow Cytometry (FACS
 
Ò
 
).
 
Human recombinant G-CSF and
IL-6 were biotinylated by using NHS-LC-biotin (Pierce Chemi-
cal Co., Rockford, IL) following the manufacturer’s procedure.
Single cell suspensions of fetal liver and spleen cells were washed
twice with PBS and then incubated at 4
 
8
 
C for 1 h with biotiny-
lated G-CSF (25 ng/10
 
6
 
 cells) or IL-6 (25 ng/10
 
6
 
 cells). After
washing twice with PBS, the cells were incubated with PE-con-
jugated streptavidin. Cells were analyzed on a FACScan
 
Ò
 
 flow
cytometer (Becton Dickinson, San Jose, CA). G-CSF and IL-6
(without biotinylation) were used as controls.
 
Retrovirus Infection of G-CSF Receptor–expressing Retroviruses.
 
For retroviral transduction experiments, the murine G-CSF re-
ceptor cDNA (the EcoRI/XhoI fragment) was inserted into the
MND-X-SN retroviral plasmid (34). This construct was stably
transfected into the GP
 
1
 
E86 packaging cell line (35). Cells were
maintained in HXM (10% fetal bovine serum, 15 
 
m
 
g/ml of hy-
poxanthine, 250 
 
m
 
g/ml xanthine, 25 
 
m
 
g/ml mycophenolic acid)
and 0.8 mg/ml G418. The titer of the retrovirus from this pro-
 
ducer line was 5 
 
3 
 
10
 
5
 
 PFU/ml. For infection of fetal liver, pro-
ducer cells were plated the day before cocultivation. The follow-
ing day, when the cells were 80–90% confluent, they were
irradiated with a single dose of 3,000 rad from a 
 
137
 
Cs source. Sin-
gle cell suspensions from C/EBP
 
a 
 
wild-type, 
 
1
 
/
 
2
 
, or 
 
2
 
/
 
2
 
 fetal
livers were washed with PBS. After lysis of red blood cells with
ACK (0.15 M MH
 
4
 
Cl, 1.0 mM KHCO
 
3
 
, 0.1 mM Na
 
2
 
EDTA,
pH 7.3), the cells were resuspended in IMDM medium contain-
ing 10% SCF (Chinese hamster ovary cell conditioned–medium)
and 8 
 
m
 
g/ml polybrene. The cells were divided into two cultures,
one with retrovirus producer cells, one without. 20 h later, cells
were harvested and plated in methylcellulose.
 
Results
 
C/EBP
 
a
 
2
 
/
 
2
 
 Murine Myeloid Progenitors Do Not Respond
to IL-6.
 
Because of the differences in phenotype between
C/EBP
 
a
 
2
 
/
 
2
 
 and G-CSF receptor
 
2
 
/
 
2
 
 mice, we suspected
that other cytokine signaling pathways in addition to
G-CSF may be adversely affected in C/EBP
 
a
 
2/2 mice.
Therefore, to investigate the response of C/EBPa-defi-
cient cells to various cytokines, methylcellulose CFU assays
were performed using liver hematopoietic cells. As shown
in Table 1, the total colony numbers from 2/2 mice are
quantitatively equal to those from wild-type mice in the
presence of GM-CSF and IL-3. We also observed mature
granulocytes in colonies derived from C/EBPa2/2 mice in
the presence of IL-3 or GM-CSF, as shown in Fig. 1. The
Table 1. In Vitro Hematopoiesis and Differentiation of Wild-type and C/EBPa2/2 Cells
CSF
Colonies
Segmented neutrophils Wild-type 2/2
% wild-type
IL-6 134 6 25 2.0 6 1.4 ,1
IL-6 1 soluble IL-6 receptor 200 6 49 26 6 11 3.4 6 1.8
IL-6 1 soluble IL-6 receptor 1 G-CSF 266 6 50 82 6 40 12 6 4.8
G-CSF 150 6 70 0.5 6 1 ,1
G-CSF 1 G-CSF receptor 148 6 66 63 6 28 66 6 26
IL-6 1 soluble IL-6 receptor 1 G-CSF 227 6 58 37 6 11 39 6 23
IL-6 1 soluble IL-6 receptor 1 G-CSF 1
G-CSF receptor retrovirus 192 6 23 46 6 11 84 6 12
IL-3 249 6 25 217 6 86 35 6 18
GM-CSF 181 6 81 163 6 57 40 6 5.7
Fetal liver cells (105 cells for CFU-G and CFU-IL6, and 2 3 104 cells for CFU-IL3 and CFU-GM) were plated in methylcellulose medium contain-
ing the indicated cytokines. The concentration of cytokines is as described in Materials and Methods. Colonies containing .50 cells were counted
after 6–7 d. Three to five animals of each genotype were analyzed. Wild-type animals (1/1) gave a result similar to that obtained from heterozygous
animals (1/2). The number of CFU-IL6 from C/EBPa2/2 livers was derived from only three colonies in one plate, which morphologically showed
all macrophages after cytocentrifugation of the colonies onto slides and staining with Wright-Giemsa. Differential counts were performed as follows:
two to four colonies were pooled from each plate on two successive days and cytocentrifuged onto glass slides. The slides were stained with Diff-
Quik solution. The percentages of segmented granulocytes were determined by counting 200–300 cells from each slide, and calculating the percent-
age of granulocytes in knockout colonies compared with that in wild-type. Each number was derived from 3 to 4 individual animals and a total of at
least 16 colonies for CFU-G and CFU-IL6.1176 IL-6 and G-CSF Receptors in Granulopoiesis
percentage of segmented neutrophils in IL-3–responsive
CFU (CFU-IL3) and CFU–GM-CSF derived from C/
EBPa2/2 fetal liver is much lower than those from wild-
type mice. In contrast, the percentage of myeloblasts in C/
EBPa2/2 mice is much higher than in wild-type mice in
CFU assays performed in the presence of IL-3 and GM-
CSF, as shown in Table 2. In cultures of C/EBPa wild-
type hematopoietic progenitors, IL-6–stimulated colonies
contained immature and mature granulocytic cells and ma-
ture macrophages. However, C/EBPa-deficient cells did
not respond to IL-6 (Table 1). These results indicate that
C/EBPa2/2 mice have myeloid precursors that responded
to IL-3 and GM-CSF in vitro, but that there is no such
population that responded to IL-6.
Mutation of C/EBPa Results in Drastically Decreased Expres-
sion of IL-6 Receptor and G-CSF Receptor mRNA. To ex-
amine whether IL-6 receptor expression is defective in
C/EBPa2/2 mice, we first performed Northern blot analy-
sis. As shown in Fig. 2 A, IL-6 receptor mRNA was
detected from the liver of day 19 C/EBPa1/2 embryos.
The signal is weaker than that detected in RNA from adult
bone marrow, peritoneal cells after thioglycollate stimula-
tion, spleen, and liver (data not shown). We did not de-
tect any hybridization from total RNA from the liver of
day 19 C/EBPa2/2 embryos (Fig. 2 A, lane 2). However,
we could detect IL-6 receptor using poly A1 mRNA from
the liver of 2/2 day 19 embryos (Fig. 2 A, lane 4). To
quantitate the expression level of IL-6 receptor mRNA,
we performed quantitative PCR using RNA from livers of
C/EBPa2/2 and wild-type mice. The results of the quanti-
tative PCR are shown in Fig. 2 B. The number of IL-6 re-
ceptor molecules per microgram of total liver RNA from
wild-type mice was very similar to that published previ-
ously (33). The number of IL-6 receptor mRNA mole-
cules was dramatically reduced in 2/2 mice, 170-fold
lower than in wild-type animals. The number of gp130
molecules from 2/2 mice was comparable to the number
found in wild-type mice, and the number of G-CSF recep-
tor molecules from 2/2 livers was 17-fold lower than in
wild-type livers (data not shown). These results further
support the notion that C/EBPa regulates G-CSF receptor
not only in vitro (5), but also in vivo. Our results also sug-
gest that C/EBPa directly or indirectly regulates IL-6 re-
ceptor but not gp130 mRNA expression in vivo.
Hematopoietic Cells in C/EBPa Mutant Mice Have Unde-
tectable IL-6 Receptor and G-CSF Receptor Protein Levels.
Our quantitative PCR results demonstrated very low levels
of G-CSF receptor and IL-6 receptor mRNA, and showed
that progenitor cells from C/EBPa2/2 mice did not re-
spond to G-CSF and IL-6 in vitro or in vivo (18). To de-
termine the protein levels of IL-6 receptor and G-CSF re-
ceptor expression, hematopoietic cells from the liver of C/
EBPa wild-type and 2/2 mice were labeled separately
with biotinylated G-CSF and IL-6 followed by PE–con-
jugated streptavidin. After staining, the cells were analyzed
by FACSÒ. As shown in Fig. 3, A, C, and E, G-CSF recep-
tor–positive and IL-6 receptor–positive cell populations are
easily detected in C/EBPa1/2 fetal liver and spleen, but
there are no such populations detected in 2/2 mice (Fig.
3, B, D, and F). Therefore, the expression of G-CSF re-
ceptor and IL-6 receptor on the surface of C/EBPa2/2
cells is undetectable. The number of G-CSF receptors on
mature granulocytes is much higher than on immature my-
eloid cells (36), and C/EBPa2/2 animals do not make ma-
ture granulocytes. One possible explanation for the low
level of G-CSF receptors detected in C/EBPa2/2 mice is
Table 2. Differential Counts of CFU Assays
Growth factor Genotype Segmented neutrophils Macrophage Immature
%% %
GM-CSF 1/2 53.8 6 13.8 6.5 6 3.5 39.8 6 10.2
2/2 20.7 6 2.3 7.2 6 1.9 72.2 6 0.8
IL-3 1/2 51.0 6 6.2 11.7 6 1.5 40.7 6 4.9
2/2 17.3 6 7.0 7.2 6 3.3 75.5 6 10.3
IL-6 1 soluble IL-6 receptor 1/2 38.7 6 8.4 33.0 6 6.3 28.3 6 2.3
2/2 1.2 6 0.3 48.3 6 8.7 50.5 6 9.0
G-CSF 1 G-CSF receptor 1/2 43.0 6 14.7 23.1 6 11.7 34.3 6 3.3
2/2 26.0 6 5.4 22.3 6 7.6 51.7 6 3.3
G-CSF 1 IL-6 1 soluble IL-6 receptor 1/2 46.1 6 9.4 31.6 6 11.4 22.3 6 4.6
2/2 16.5 6 6.4 37.2 6 6.8 46.3 6 8.1
G-CSF 1 IL-6 1 G-CSF receptor 1 soluble IL-6 receptor 1/2 48.7 6 8.7 33.1 6 2.5 18.1 6 11.4
2/2 40.6 6 5.5 33.3 6 7.0 22.5 6 8.3
Using the colonies generated as described in the legend to Table 1, percentages of different types of cells were determined by counting 200–300 cells
from each slide. Each number was derived from a total of 3 to 4 individual animals, and at least 16 colonies for CFU-G and CFU-IL6. Immature cells
include myeloblasts and metamyelocytes; segmented neutrophils include band forms.1177 Zhang et al.
Figure 1. GM-CSF and IL-3 can stimulate C/EBPa2/2 fetal liver cells to differentiate to mature granulocytes. (A–D) Representative views of cells
from colonies obtained in CFU assays (Table 1) from C/EBPa1/2 (A and C) and 2/2 (B and D) fetal liver in the presence of GM-CSF or IL-3 after 7 d
in methylcellulose culture. Two to three colonies from each plate were pooled, cytocentrifuged onto slides, and stained with Wright-Giemsa. (E and F)
The same cells were grown in liquid culture in the presence of IL-3 and SCF for 5 d. E shows cells derived from 1/2 mice, and F from 2/2 mice.
Identical results were obtained after culture with GM-CSF. We were also not able to distinguish differences between cells obtained from wild-type and
heterozygous animals in any of the experiments in this study.1178 IL-6 and G-CSF Receptors in Granulopoiesis
the absence of mature granulocytes in the liver and spleen.
Therefore, hematopoietic cells from C/EBPa heterozy-
gous and 2/2 fetal liver were cultured in suspension in
the presence of SCF and IL-3 to stimulate both heterozy-
gous and 2/2 cells towards mature granulocytic differen-
tiation. As shown below, SCF alone does not promote
granulocyte differentiation or development, but was added
to the cultures to promote viability in the absence of other
growth factors. After 5 d in culture with IL-3, the cells
were cytocentrifuged onto slides and subsequently stained
with Wright-Giemsa. Mature granulocytes appeared in
both heterozygous and 2/2 cultures, but the percentage
of mature granulocytes in heterozygous cultures was higher
than that observed in the 2/2 cultures, similar to what
was observed in the CFU assays (Fig. 1, E and F). The cells
were harvested and then stained with biotinylated G-CSF
and IL-6. As shown in Fig. 3, G–J, we still failed to observe
G-CSF receptor and IL-6 receptor–positive cells from 2/2
compared with wild-type mice, even after culture in IL-3
induced morphologic maturation in which z30% of the
cells were metamyelocytes or segmented granulocytes.
These results indicated that although mature segmented
granulocytes are not present in vivo in C/EBPa mice,
stimulation of C/EBPa2/2 hematopoietic cells with cyto-
kines like GM-CSF and IL-3 can induce the formation of
cells which have the morphologic appearance of mature
cells yet still do not express G-CSF receptor and IL-6 re-
ceptor. Therefore, the absence of G-CSF receptor and IL-6
receptor is not simply a result of absence of mature cells,
and the G-CSF receptor and IL-6 receptor are truly regu-
lated, either directly or indirectly, by C/EBPa in vivo.
IL-6 and Soluble IL-6 Receptor Together Can Rescue C/
EBPa Granulopoiesis In Vitro. These results suggest that
lack of IL-6 and G-CSF signaling due to loss of both IL-6
and G-CSF receptors contributes to the block of granulo-
cyte maturation in C/EBPa2/2 mice. This phenotype
could potentially be rescued by restoration of the receptors
on the surface of the cells. The cytoplasmic domain of the
IL-6 receptor is not required for IL-6 binding and signal
transduction, as IL-6 can bind to soluble IL-6 receptor and
Figure 2. IL-6 receptor
mRNA is markedly decreased in
C/EBPa2/2 mice. (A) Northern
blot analysis of IL-6 receptor
mRNA. 15 mg of total RNA
from C/EBPa1/2 day 19 fetal
liver (lane 1) and C/EBPa2/2
day 19 fetal liver (lane 2), and 2
mg of poly A1 RNA from C/
EBPa1/2 day 19 fetal liver (lane
3) and 2/2 day 19 fetal liver
(lane  4) were electrophoresed in 1% agarose/formaldehyde gels, transferred to nylon membranes, and hybridized to a murine IL-6 receptor cDNA (refer-
ence 26). The position of the IL-6 receptor mRNAs (left) and the 28S and 18S RNAs (right) are shown. Below the total RNA blot (left) are shown the
results of hybridization of an 18S ribosomal RNA oligonucleotide to the blot (59-TCGGGCCTGCTTTGAACA-39 [reference 51]), and below the poly
A1 blot (right) are shown the results of hybridization of a GAPDH probe (reference 52). (B) Quantitative RT-PCR analysis of IL-6 receptor mRNA.
Above the autoradiograph are indicated the numbers of molecules of competitor RNA. The first five lanes are sample RNAs (2 mg/lane) from C/EBPa
wild-type fetal liver, and the last five lanes are from C/EBPa2/2 fetal liver RNA. The locations of the standard and IL-6 receptor–amplified PCR prod-
ucts are indicated (left).
Figure 3. Flow cytometry analy-
sis with biotinylated IL-6 and G-CSF.
Cells from C/EBPa1/2 (A and C)
or C/EBPa2/2 (B and D) day 17
fetal liver or from 1/2 (E) or 2/2
(F) day 17 fetal spleen were stained
with biotinylated G-CSF (A and B)
or biotinylated IL-6 (C–F). Cells
from C/EBPa1/2 (G and I) or C/
EBPa2/2 (H and J) were cultured
in IL-3 and SCF for 5 d and then
stained with biotinylated G-CSF (G
and H) or biotinylated IL-6 (I and
J). b, The FACSÒ profiles using bi-
otinylated factor (G-CSF or IL-6);
bar, the profiles using unbiotiny-
lated factor, which serves as a con-
trol. In the bottom row, the profiles
using biotinylated and unbiotiny-
lated factor are superimposable.
y-axis, Number of events (10,000
events counted in each panel); x-axis,
log10 fluorescence.1179 Zhang et al.
this complex can trigger gp130 to transduce a signal on
cells that lack the IL-6 receptor (31). Therefore, fetal liver
suspension cells from both wild-type and 2/2 day 14 to
day 16 embryos were used in CFU assays in the presence of
IL-6 plus soluble IL-6 receptor, and IL-6 plus soluble IL-6
receptor plus G-CSF, respectively (Table 1). There were
significant numbers of colonies generated from wild-type
mice in the presence of IL-6 plus soluble IL-6 receptors
which were morphologically CFU-GM. When G-CSF
was also added, both the colony number and the percent-
age of mature granulocytes increased as well (Tables 1 and
2; Fig. 4, A and C). Compared with those from wild-
type animals, the colony numbers from C/EBPa2/2 cells
in the presence of IL-6 and soluble IL-6 receptor were
lower, but a small number of metamyelocytes and seg-
mented neutrophils appeared from the colonies after day 6
as shown in Fig. 4 B. Most of cells in the 2/2 colony
were immature cells. Interestingly, increases in colony
numbers and percentage of more mature segmented granu-
locytes were observed in C/EBPa2/2 mice after the addi-
tion of G-CSF to the IL-6 plus soluble IL-6 receptor cul-
ture as shown in Fig. 4 D. These results indicated that IL-6
plus soluble IL-6 receptor can partially rescue the C/EBPa
phenotype in vitro but does not efficiently induce terminal
maturation of granulocytes.
Restoration of G-CSF Receptor Expression Can Restore the
Production of Mature Granulocytes In Vitro. Granulocyte mat-
uration was completely blocked in C/EBPa2/2 mice in
vivo. This phenotype can only be partially rescued by IL-6
signaling in vitro. Since G-CSF receptors were undetect-
able in C/EBPa2/2 mice, rescue experiments were per-
formed by transduction of G-CSF receptors into the cells
using retrovirus infection. Day 15 fetal liver hematopoietic
cells from C/EBPa2/2 and heterozygous mice were cul-
Figure 4. Mature granulocytes
are observed after rescue by solu-
ble IL-6 receptor and G-CSF re-
ceptor retrovirus. (A, C, and E)
Cells from C/EBPa1/2 fetal
liver. (B, D, and F) Cells from
C/EBPa2/2 fetal liver. A and B
show cells from CFU assays with
IL-6 and soluble IL-6 receptor in
the medium; C and D, CFU
with IL-6, soluble IL-6 receptor,
and G-CSF in the medium. E
and F show CFU after infection
of fetal liver cells with the
G-CSF receptor retrovirus de-
scribed in the legend to Fig. 5
followed by culture in methyl-
cellulose in the presence of G-CSF
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tured with or without murine G-CSF receptor retrovirus
producer cells in the presence of SCF (added to promote
cell viability) and polybrene. After 20–22 h, cells were har-
vested and were plated in methylcellulose in the presence
of G-CSF (Table 1). In addition, cells were maintained in
the same culture conditions without polybrene for an addi-
tional 4 d and stained with biotinylated G-CSF to demon-
strate induction of high levels of G-CSF receptor by the
retrovirus (Fig. 5). Colony numbers from C/EBPa het-
erozygous mice were not significantly different with or
without G-CSF receptor retrovirus infection. No colonies
were observed in cultures from C/EBPa2/2 mice without
retrovirus infection, or with retrovirus infection but cul-
tured in the absence of added G-CSF. Infected cells from
C/EBPa heterozygous mice also yielded no colonies when
cultured without G-CSF. Colonies were observed from
G-CSF receptor retrovirus–infected C/EBPa2/2 cells in
the presence of G-CSF, but less than the number from C/
EBPa heterozygous hematopoietic cells after retrovirus in-
fection (Table 1). Mature granulocytes could be detected in
the 2/2 colonies (Fig. 4 F). Interestingly, when infected
cells were plated in medium in the presence of IL-6 and
soluble IL-6 receptor in addition to G-CSF, the colony
numbers were only slightly increased, but the percentage of
mature granulocytes from C/EBPa2/2 cells was increased
to almost the same level as that from C/EBPa heterozy-
gous mice (Tables 1 and 2). Therefore, restoration of both
IL-6 receptor and G-CSF receptor levels restored granulo-
cyte production in vitro.
Discussion
Previously, we had reported that granulocyte differentia-
tion and maturation were selectively blocked, and the ex-
pression of G-CSF receptor mRNA could not be detected
by Northern blot analysis in cells from mice with a targeted
disruption of the C/EBPa gene. However, mice with a
targeted disruption of either G-CSF (37) or G-CSF recep-
tor (19) show a decrease only in the number of peripheral
blood neutrophils but are not blocked in maturation.
Therefore, other mechanisms in addition to G-CSF are in-
volved for induction of granulopoiesis. In this paper, we
show that hematopoietic cells from C/EBPa2/2 fetal liver
can form CFU-GM in the presence of IL-3 or GM-CSF in
vitro. However, the percentage of mature granulocytes is
lower in 2/2 than in wild-type cells. These results indi-
cate that immature myeloid progenitors are present in C/
EBPa2/2 mice, and those progenitors respond to GM-CSF
and IL-3. Interestingly, these cells do not mature in re-
sponse to retinoic acid, a potent inducer of granulocytic
differentiation (38), given both in vivo and in vitro (data
not shown). These immature cells also do not respond to
IL-6 and G-CSF in vitro. There are several possible expla-
nations for why GM-CSF and IL-3 could stimulate mye-
loid precursors to differentiate into mature granulocytes in
vitro, but granulocytes are not observed in vivo. First,
GM-CSF and IL-3 are not normally produced in the bone
marrow, but by activated T cells and mast cells (39). Fetal
T cells and mast cells are not normally activated by patho-
gens because of the protection of the placental barrier.
Consistent with this hypothesis, neither GM-CSF nor IL-3
could be detected in adult bone marrow, during embryonic
stem cell differentiation by RT-PCR or during in vitro
culture of embryonic blastocysts (40, 41). These studies
suggest that the fetus does not produce its own IL-3 and
GM-CSF. To investigate whether IL-3 could rescue gran-
ulopoiesis in vivo, we administered IL-3 into a C/EBPa1/2
pregnant female that had mated with a C/EBPa1/2 male.
Day 19 embryos were analyzed, but no mature granulo-
cytes could be detected in C/EBPa2/2 peripheral blood or
fetal liver. However, since no changes were detected in
C/EBPa wild-type fetuses as well, it is possible that IL-3
and GM-CSF may, like erythropoietin (42) but not G-CSF
(43), be unable to cross the placental barrier. Mice deficient
in the entire IL-3/GM-CSF/IL-5 signaling pathway re-
vealed normal numbers of total peripheral leukocyte counts
and differential counts except for eosinophils (44). These
results suggest that GM-CSF and IL-3 are not necessary for
Figure 5. Transduction of G-CSF recep-
tor using retroviral infection of C/EBPa2/2
fetal liver cells. The histograms represent
analysis of surface expression of G-CSF re-
ceptors on cells from C/EBPa heterozygous
(A and B) and C/EBPa2/2 (C and D) with-
out (A and C) or after (B and D) infection
with a murine G-CSF receptor expressing
retrovirus, followed by culture in the pres-
ence of SCF only for 5 d, then FACSÒ anal-
ysis after staining with biotinylated G-CSF.
b and bar, Profiles obtained with biotiny-
lated and unbiotinylated G-CSF, respec-
tively. y-axis, Number of events (10,000
events counted in each panel); x-axis, log10
fluorescence. RV, Retrovirus.1181 Zhang et al.
routine production of mature neutrophils. These two fac-
tors may play a major role in expansion of hematopoietic
cells in emergency situations (39). IL-3 and GM-CSF share
a common b chain receptor which signals by inducing pro-
tein phosphorylation of similar proteins (45); the two cy-
tokines can also compete with each other in binding to
their high-affinity receptors (46). All of these studies sug-
gest that there may be a cell population in mice that ex-
presses both GM-CSF and IL-3 receptors on the cell sur-
face. This population apparently exists in the C/EBPa2/2
mice, but because there is no GM-CSF and IL-3 in the fe-
tus, this population might not differentiate in vivo but
could nevertheless differentiate in vitro after stimulation
with IL-3 and GM-CSF.
The absence of G-CSF signaling alone could not explain
the phenotype of C/EBPa-deficient mice, and IL-6 is an-
other important growth factor for myeloid cell prolifera-
tion and differentiation (20–22). Our previous studies sug-
gested that G-CSF receptor and IL-6 receptor stimulated
the same myeloid progenitors (19). Therefore, in addition
to the G-CSF receptor, the IL-6 receptor could be a candi-
date target for the C/EBPa transcription factor, and in-
deed, the number of CFU–IL6 is drastically reduced in
C/EBPa2/2 mice. The phenotype of mice deficient in
the IL-6 signal transducer gp130 is distinct from that of
C/EBPa2/2 mice (47), so we focused our studies on the
expression of the IL-6 receptor. Like G-CSF receptor, IL-6
receptor could not be detected by Northern blot analysis of
total fetal liver RNA from C/EBPa2/2 mice. By quantita-
tive RT-PCR, IL-6 receptor could be detected, but IL-6
receptor mRNA in C/EBPa2/2 mice is 170-fold lower
than in wild-type mice. As expected, the expression of
gp130 is normal in C/EBPa2/2 compared with wild-type
mice. Staining of hematopoietic cells from C/EBPa wild-
type and 2/2 fetal liver with biotinylated G-CSF and IL-6
demonstrated no surface G-CSF receptor and IL-6 recep-
tor–positive cell populations in C/EBPa2/2 mice. When
C/EBPa2/2 cells were induced to differentiate to mature
granulocytes with IL-3 and SCF or GM-CSF and SCF, the
morphologically mature cells are still IL-6 and G-CSF re-
ceptor–negative. These findings demonstrate that C/EBPa
is a major regulator for both IL-6 receptor and G-CSF re-
ceptor in vivo, and mature cells from IL-3 and GM-CSF
stimulation in vitro do not express IL-6 and G-CSF recep-
tors. The proliferation and survival of these cells depend on
IL-3 and GM-CSF but not IL-6 and G-CSF. Mice with a
disruption of the IL-6 gene fail to efficiently control infec-
tion with vaccinia virus and Listeria monocytogenes, a faculta-
tive intracellular bacterium, and in these animals the in-
flammatory acute-phase response after tissue damage or
infection is severely compromised (48). Consistent with
this report and our current findings is the additional obser-
vation that the acute-phase response is completely lacking
in these same C/EBPa2/2 mice (Burgess-Beusse, B.L., and
G.J. Darlington, manuscript in preparation), perhaps due in
part to the loss of IL-6 receptor expression.
Because hematopoietic cells from C/EBPa2/2 mice lack
normal numbers of IL-6 receptors, no colonies were ob-
served in CFU assays from C/EBPa2/2 cells when stimu-
lated with IL-6 only. IL-6 can bind to the soluble form of
the IL-6 receptor, and can trigger gp130 signaling on target
cells lacking the IL-6 receptor but expressing gp130. When
soluble IL-6 receptor and IL-6 were added to C/EBPa2/2
cells, CFU-IL6 were observed at a level 30% that of wild-
type cells. Interestingly, the addition of G-CSF to the cul-
tures with IL-6 and soluble IL-6 receptor resulted in in-
creased numbers of colonies and percentage of mature
granulocytes in the colonies. Previously, it has been reported
that IL-6 stimulates stem cells in their ability to respond to
IL-3, and when IL-6 is combined with other recombinant
hematopoietic factors, including G-CSF, it can augment
responses to these factors or even modify them (49). The
results presented here suggest that G-CSF signaling may be
one of the growth factor pathways whose function can be
augmented by IL-6.
The block of granulocytic differentiation in C/EBPa2/2
mice can only be partially rescued in vitro by restoration of
IL-6 receptor. Therefore, we infected fetal liver cells from
C/EBPa wild-type and 2/2 mice with a retrovirus ex-
pressing the wild-type G-CSF receptor. When the cells
were placed in culture without added growth factors, no
colonies were detected after retrovirus infection from both
wild-type and 2/2 mice. When infected cells from the C/
EBPa2/2 mice were cultured in the presence of G-CSF,
cells from 2/2 liver generated half the number of colonies
compared with wild-type liver, and these colonies con-
tained mature granulocytes in addition to macrophages and
immature myeloid cells. With the addition of IL-6 and sol-
uble IL-6 receptor to the same cultures, the colony number
was still lower than in wild-type. Furthermore, our recent
Figure 6. Two models of granulocytic development. (A) A pluripoten-
tial stem cell differentiates into an immature multipotent myeloid progen-
itor, perhaps under the influence of transcription factors such as PU.1
(reference 2). This cell can then further differentiate to a mature granulo-
cyte, either via a CFU-G/CFU-IL6 precursor which is dependent upon
C/EBPa function, or via a CFU–IL3/CFU-GM precursor which is C/
EBPa independent. (B) The multipotent progenitor differentiates into an
early granulocytic precursor that can respond to IL-3 and/or GM-CSF,
which itself is induced to differentiate further under the influence of C/
EBPa to a precursor that responds to G-CSF and/or IL-6.1182 IL-6 and G-CSF Receptors in Granulopoiesis
studies have shown that the IL-6 and G-CSF receptor dou-
ble knockout phenotype is similar to that of the G-CSF re-
ceptor alone and, unlike the C/EBPa2/2 mouse, still
makes mature granulocytes. These results suggest that in
addition to the IL-6 and G-CSF receptor, some other genes
are affected in the C/EBPa2/2 mice (15a). Since the G-CSF
receptor and gp130 have a similar intracellular domain and
activate similar signaling pathways, our combined data sug-
gest that there is a G-CSF and IL-6 receptor–positive cell
population in mice. The generation of mature granulocytes
from this population of cells is blocked due to the lack of
IL-6 and G-CSF responsiveness, but another population
can respond, at least in vitro, to IL-3 and GM-CSF.
Whether such a population exists in vivo can potentially be
addressed once mice with selective restoration of C/EBPa
expression in liver and not blood, and with longer viability,
are produced.
In summary, we demonstrate that C/EBPa may directly
or indirectly regulate the IL-6 receptor. In the absence of
C/EBPa, we observed a marked decrease in IL-6 and
G-CSF receptor expression. Neither IL-6 nor G-CSF sig-
naling is required for myeloid cell lineage commitment, but
they are likely to play an important role in proliferation
and/or viability of myeloid precursors. Our results raise the
very interesting possibility (Fig. 6 A) that two distinct pop-
ulations of granulocyte-macrophage progenitors are present
in the murine hematopoietic system, one G-CSF and IL-6
dependent and the other IL-3 and GM-CSF dependent.
Alternatively, granulocyte development occurs in several
stages, beginning with an IL-3 and GM-CSF–responsive
precursor, which itself can further differentiate to become
responsive to G-CSF and IL-6 (Fig. 6 B). This latter model
is more consistent with the hierarchical expression of CSF
receptors (50). Our data tend to support the first model
(Fig. 6 A). At least in vitro, loss of C/EBPa mainly affects
the G-CSF/IL-6–dependent precursor, and stimulation of
either IL-3 or GM-CSF can induce granulocyte formation.
If such a model is correct, it remains to be determined why
this latter pathway is incapable of inducing formation of
mature granulocytes in C/EBPa knockout animals.
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